Fatal bone-marrow suppression associated with captopril.
作者信息
el-Makri A, Larabi M S, Kechrid C, Belkahia C, Ben Ayed H
出版信息
Br Med J (Clin Res Ed). 1981 Jul 25;283(6286):277-8. doi: 10.1136/bmj.283.6286.277-a.
Abstract
摘要
相似文献
1
Fatal bone-marrow suppression associated with captopril.与卡托普利相关的致命性骨髓抑制。
Br Med J (Clin Res Ed). 1981 Jul 25;283(6286):277-8. doi: 10.1136/bmj.283.6286.277-a.
2
Fatal bone-marrow suppression associated with captopril.与卡托普利相关的致命性骨髓抑制。
Br Med J (Clin Res Ed). 1981 Sep 19;283(6294):791-2. doi: 10.1136/bmj.283.6294.791-b.
3
Fatal pancytopenia associated with the use of captopril.与使用卡托普利相关的致命性全血细胞减少症。
Ann Intern Med. 1981 Jan;94(1):58-9. doi: 10.7326/0003-4819-94-1-58.
4
Captopril-induced pancytopenia in a premature newborn.卡托普利致早产新生儿全血细胞减少症
J Paediatr Child Health. 2004 Jul;40(7):404-5. doi: 10.1111/j.1440-1754.2004.00412.x.
5
[Usefulness of combined captopril-labetalol treatment in resistant hypertension (author's transl)].
Nouv Presse Med. 1982 May 8;11(21):1611-3.
6
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)].
Nouv Presse Med. 1981 Apr 30;10(19):1575-8.
7
Pancytopenia associated with administration of captopril to a dog.一只狗使用卡托普利后出现全血细胞减少。
J Am Vet Med Assoc. 1996 May 15;208(10):1683-6.
8
[Nifedipine, captopril and labetalol--overviews on the pattern of adverse effects].硝苯地平、卡托普利和拉贝洛尔——不良反应模式综述
Lakartidningen. 1985 Jul 10;82(28-29):2531-2.
9
[Hepatitis during captopril combination therapy].[卡托普利联合治疗期间的肝炎]
Therapie. 1982 Nov-Dec;37(6):698-700.
10
Cough associated with the use of captopril.与使用卡托普利相关的咳嗽。
Arch Intern Med. 1985 Aug;145(8):1524.
引用本文的文献
1
HLA-DR2 Frequency Increase in Severe Aplastic Anemia Patients is Mainly Attributed to the Prevalence of DR15 Subtype.重型再生障碍性贫血患者中HLA-DR2频率增加主要归因于DR15亚型的流行。
Pathol Oncol Res. 1997;3(2):106-108. doi: 10.1007/BF02907803.
2
Low dose captopril in the treatment of severe refractory hypertension associated with renal failure.低剂量卡托普利治疗与肾衰竭相关的严重难治性高血压
Postgrad Med J. 1982 Jul;58(681):419-21. doi: 10.1136/pgmj.58.681.419.
3
Reversible captopril-associated bone marrow aplasia.可逆性卡托普利相关性骨髓再生障碍。
Can Med Assoc J. 1985 Feb 15;132(4):320-2.
4
Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.卡托普利。其药效学和药代动力学特性的最新进展，以及在高血压和充血性心力衰竭中的治疗应用。
Drugs. 1988 Nov;36(5):540-600. doi: 10.2165/00003495-198836050-00003.
5
Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.血管紧张素转换酶（ACE）抑制剂的不良反应。
Med Toxicol. 1986 Mar-Apr;1(2):122-41. doi: 10.1007/BF03259832.
本文引用的文献
1
Fatal pancytopenia associated with the use of captopril.与使用卡托普利相关的致命性全血细胞减少症。
Ann Intern Med. 1981 Jan;94(1):58-9. doi: 10.7326/0003-4819-94-1-58.
2
Captopril associated granulocytopenia in hypertension after renal transplantation.肾移植后高血压患者中卡托普利相关的粒细胞减少症
Lancet. 1980 Apr 26;1(8174):927-8. doi: 10.1016/s0140-6736(80)90854-5.
3
Captopril and agranulocytosis.卡托普利与粒细胞缺乏症
Lancet. 1980 Apr 26;1(8174):926-7. doi: 10.1016/s0140-6736(80)90853-3.
4
Captoril-associated agranulocytosis.卡托普利相关性粒细胞缺乏症。
Lancet. 1980 Jan 19;1(8160):150.
5
Captopril-associated agranulocytosis.卡托普利相关性粒细胞缺乏症。
Lancet. 1980 Jan 19;1(8160):150. doi: 10.1016/s0140-6736(80)90629-7.
Zotero 插件